151 related articles for article (PubMed ID: 28761897)
1. The Dose-Dependent Efficacy of Cefepime in the Empiric Management of Febrile Neutropenia: A Systematic Review and Meta-Analysis.
Andreatos N; Flokas ME; Apostolopoulou A; Alevizakos M; Mylonakis E
Open Forum Infect Dis; 2017; 4(3):ofx113. PubMed ID: 28761897
[TBL] [Abstract][Full Text] [Related]
2. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials.
Paul M; Yahav D; Fraser A; Leibovici L
J Antimicrob Chemother; 2006 Feb; 57(2):176-89. PubMed ID: 16344285
[TBL] [Abstract][Full Text] [Related]
3. [Cefepime as an empiric treatment of febrile neutropenia in patients after high dose therapy and autologous stem cell transplantation].
Zikesoá E; Hnátková M; Vacková B; Jedlicková A; Klener P; Trnený M
Cas Lek Cesk; 2006; 145(5):383-6, 388-9. PubMed ID: 16755776
[TBL] [Abstract][Full Text] [Related]
4. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer.
Chuang YY; Hung IJ; Yang CP; Jaing TH; Lin TY; Huang YC
Pediatr Infect Dis J; 2002 Mar; 21(3):203-9. PubMed ID: 12005083
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia.
Mustafa MM; Carlson L; Tkaczewski I; McCracken GH; Buchanan GR
Pediatr Infect Dis J; 2001 Mar; 20(3):362-9. PubMed ID: 11303851
[TBL] [Abstract][Full Text] [Related]
6. Cefepime vs. cefoperazone/sulbactam in combination with amikacin as empirical antibiotic therapy in febrile neutropenia.
Ponraj M; Dubashi B; Harish BH; Kayal S; Cyriac SL; Pattnaik J; Ranjith K; Pillai US; Jadhav N; Matta KK; Singh J; Jaffa E; Prakash B
Support Care Cancer; 2018 Nov; 26(11):3899-3908. PubMed ID: 29774477
[TBL] [Abstract][Full Text] [Related]
7. Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.
Jimeno A; Arcediano A; Bazares S; Amador ML; González-Cortijo L; Ciruelos E; Robles L; Castellano D; Paz-Ares L; Lumbreras C; Hornedo J; Cortés-Funes H
Clin Transl Oncol; 2006 Dec; 8(12):889-95. PubMed ID: 17169762
[TBL] [Abstract][Full Text] [Related]
8. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
9. Extended-interval aminoglycoside administration for children: a meta-analysis.
Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of intravenous ciprofloxacin in patients with febrile neutropenia refractory to initial therapy.
Matsuoka H; Tsukamoto A; Shirahashi A; Koga S; Suzushima H; Shibata K; Uozumi K; Yamashita K; Okamura S; Kawano F; Tamura K;
Leuk Lymphoma; 2006 Aug; 47(8):1618-23. PubMed ID: 16966275
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient.
Ramphal R; Gucalp R; Rotstein C; Cimino M; Oblon D
Am J Med; 1996 Jun; 100(6A):83S-89S. PubMed ID: 8678102
[TBL] [Abstract][Full Text] [Related]
12. Treatment of febrile neutropenia with cefepime monotherapy.
Jándula BM; Martino R; Gurgi M; Manteiga R; Sierra J
Chemotherapy; 2001; 47(3):226-31. PubMed ID: 11306793
[TBL] [Abstract][Full Text] [Related]
13. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
Sanz MA; López J; Lahuerta JJ; Rovira M; Batlle M; Pérez C; Vázquez L; Julià A; Palau J; Gutiérrez M; Capote FJ; Ramos F; Benlloch L; Larrea L; Jarque I;
J Antimicrob Chemother; 2002 Jul; 50(1):79-88. PubMed ID: 12096010
[TBL] [Abstract][Full Text] [Related]
14. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.
Wrenn RH; Cluck D; Kennedy L; Ohl C; Williamson JC
J Oncol Pharm Pract; 2018 Apr; 24(3):170-175. PubMed ID: 28077047
[TBL] [Abstract][Full Text] [Related]
15. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
Corapcioglu F; Sarper N; Zengin E
Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
[TBL] [Abstract][Full Text] [Related]
16. Cefepime monotherapy for treatment of febrile neutropenia in children.
Ariffin H; Ai CL; Lee CL; Abdullah WA
J Paediatr Child Health; 2006 Dec; 42(12):781-4. PubMed ID: 17096713
[TBL] [Abstract][Full Text] [Related]
17. A clinical evaluation of efficacy and safety of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia in a tertiary care centre of north India.
Aamir M; Abrol P; Sharma D; Punia H
Trop Doct; 2016 Jul; 46(3):142-8. PubMed ID: 26612093
[TBL] [Abstract][Full Text] [Related]
18. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function.
Lamoth F; Buclin T; Pascual A; Vora S; Bolay S; Decosterd LA; Calandra T; Marchetti O
Antimicrob Agents Chemother; 2010 Oct; 54(10):4360-7. PubMed ID: 20625153
[TBL] [Abstract][Full Text] [Related]
19. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of cephalosporin monotherapy and aminoglycoside/ureidopenicillin combination therapy. For the treatment of febrile episodes in neutropenic patients.
Paladino JA; Fong LD; Forrest A; Ramphal R
Pharmacoeconomics; 2000 Oct; 18(4):369-81. PubMed ID: 15344305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
